Fig. 3.
(a) Deduced EIAV envelope gp90 amino acid sequences (aa 122–238) obtained from A2140 V5 plasma (GenBank Accession Nox. AY288526-AY288549) as compared to the EIAVWSU5 stock used for inoculation. Only those aa different from those in EIAVWSU5 are shown. rtpcr1 and rtpcr2 were two different directly sequenced RT-PCR products. Clones designated with a “1.” were derived from the rtpcr1 product, while clones designated with a “2.” were derived from the rtpcr2 product. The Env-RW12 CTLm epitope is in bold and underlined. The hypervariable regions V2 and V4, the putative principle neutralizing domain (PND), and the two murine monoclonal neutralizing antibody epitopes ENT and DNT (Ball et al., 1992) are indicated. (b) Deduced EIAV envelope gp90 amino acid cloned sequences (aa 122–238) obtained from the EIAVWSU5 stock used for inoculation (GenBank Accession Nos. AY288550-AY288559). Only those aa different from the EIAVWSU5 consensus are shown. The Env-RW12 CTLm epitope is in bold and underlined. (c) A2140 CTLm were added to homologous EK targets pulsed with either peptide Env-RW12 or Env-HW12v at the concentrations indicated. CTLm were from PBMC obtained after V5 and stimulated for 7 days with EIAVWSU5. Effector:target cell ratio was 20:1. (d) Deduced EIAV envelope gp90 amino acid sequences (aa 182–238) obtained from A2140 V1 (DPI 24), V2 (DPI 178), between V2 and V3 (DPI 230), and V3 (DPI 285) plasmas (GenBank Accession Nos. AY288560-AY288587) as compared to the EIAVWSU5 stock used for inoculation. Only those aa different from those in EIAVWSU5 are shown. Clones are designated by the DPI from which the RT-PCR product was obtained, followed by the clone number. The Env-RW12 CTLm epitope is in bold and underlined. (e) Deduced EIAV Gag p15 amino acid sequences (aa −3–57) obtained from A2140 V5 plasma (GenBank Accession Nos. AY288588-AY288605) as compared to the EIAVWSU5 stock used for inoculation. Only those aa different from those in EIAVWSU5 are shown. The Gag-GW12 CTLm epitope is in bold and underlined.